Artrya Limited (ASX:AYA)
Australia · Delayed Price · Currency is AUD 4.810
-0.240 (-4.75%)
May 18, 2026, 4:11 PM AEST
Artrya Company Description
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease.
It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography.
The company was incorporated in 2018 and is based in West Perth, Australia.
Artrya Limited
| Country | Australia |
| Founded | 2018 |
| Industry | Health Information Services |
| Sector | Healthcare |
| CEO | John Konstantopoulos |
Contact Details
Address: 1257 Hay Street West Perth, Washington Washington Australia | |
| Phone | 61 8 6478 7816 |
Stock Details
| Ticker Symbol | AYA |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000182412 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| John Konstantopoulos B.E. | Co-Founder and Chief Executive Officer |
| Bernard William Ridgeway F.A.C.I.D. | Executive Chair |
| Richard Mark Jarvis | Chief Financial Officer |
| Phil Bowen | Chief Operations Officer |
| Prof. Girish Dwivedi M.D. | Chief Scientific Officer |
| Dr. Richard M. Stewart | Chief Regulatory Affairs and Quality Officer |
| Ryan Athearn | Head of Global Clinical Operations |
| Mark Edward Pitts F.C.A. | Company Secretary |